Plain-English translation of NCT06929013 on ClinicalTrials.gov ↗ ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying new blood markers called nucleosomes and CTCF to see if they can detect leftover cancer after surgery for colorectal cancer that has spread to the abdominal lining. Right now, doctors rely on what they see during surgery to know how well the cancer was removed, but this study is testing whether blood tests could give doctors a more objective, science-based way to know if any cancer remains. You would have blood drawn at several time points around your surgery so researchers can understand how these markers behave.
Current methods of checking whether surgery completely removed peritoneal cancer are based on what surgeons observe during the operation, which is subjective and limited. This research aims to develop an objective biological tool—measurable in blood—that could help doctors identify patients with remaining disease so they can plan better follow-up care.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would undergo your planned surgery as usual, but researchers would collect extra blood samples at specific times—before surgery, during the operation, and at set intervals afterward (such as 24 hours and 7 days post-surgery). These samples would be analyzed to measure the blood markers and understand how they change after surgery. Your participation would likely last a few weeks, with the main involvement being the additional blood draws; your actual surgery and hospital care would proceed normally.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
France